Posted On: Monday, October 19th, 2015
New and Noteworthy High cure rates for people on opiate substitution therapy with Holkira Pak A small, mid-stage clinical trial of participants on opioid substitution therapy (OST) who took Holkira Pak and ribavirin for 12 weeks had a cure rate of 97% reported researchers in the Journal of Hepatology. OST is taken by people who… Read more »
Posted On: Tuesday, October 13th, 2015
The World Health Organization/Pan-American Health Organization Action Plan for the Prevention and Control of Viral Hepatitis was approved last week during the 67th Session of the Regional Committee of WHO for the Americas in Washington, DC! The new plan not only lays out steps to reduce illnesses and deaths due to hepatitis, but also sets… Read more »
Posted On: Sunday, September 27th, 2015
New and Noteworthy Daclatasvir approved in Canada The Hep C drug daclatasvir (Daklinza) has been approved in Canada for people with genotype 1 or 2 virus. It has also been conditionally approved for people with genotype 3 virus pending the outcome of a late-stage clinical trial. Daclatasvir is taken with sofosbuvir (Sovaldi) for 12 weeks… Read more »
Posted On: Tuesday, September 22nd, 2015
Posted On: Tuesday, September 8th, 2015
In recent years, groups of gay, bi and queer men – especially HIV-positive men but also HIV-negative men – have become Hep C positive through sex. Find out more in Hep C and Sex for Gay, Bi and Queer Men; a new resource from ACT and CATIE. Order free copies for your clients from… Read more »
Posted On: Monday, August 31st, 2015
The Canadian Agency for Drugs and Technologies in Health (CADTH) wants to hear from you! They are currently seeking a patient group input report for AbbVie 2D–GT4 (ombitasvir / paritaprevir / ritonavir) and, therefore, the Pacific Hep C Network (PHCN) needs your thoughts, opinions, and experiences for our report. CADTH Patient Group Input Reports The… Read more »
Posted On: Monday, August 31st, 2015
New and Noteworthy Canadian Hep C research network receives $4.5 million grant B.C., Saskatchewan, Manitoba and Yukon add Holkira Pak to formularies FDA approves new interferon-free Hep C treatments for genotypes 3 and 4 virus
Posted On: Sunday, August 23rd, 2015
Many people in Canada are affected by hepatitis C. An estimated 332,414 people were antibody positive for hepatitis C in Canada in 2011. This means they had evidence of a current or past infection with hepatitis C. An estimated 220,697 to 245,987 Canadians had chronic hepatitis C infection in 2011. In 2014–15, CATIE undertook a… Read more »
Posted On: Wednesday, August 19th, 2015
World Hepatitis Day was held on July 28, 2015 and while there were events happening across Canada I was able to attend the event that happened in Vancouver. It was a great day! There were lots of amazing speakers talking about the status of new and more effective hepatitis C treatments (the Pacific Hepatitis C… Read more »
Posted On: Monday, August 17th, 2015
CATIE is pleased to announce the launch of the newly updated and improved websites HIV411.ca and HCV411.ca, formerly known as ASO411.ca. HIV411.ca/HCV411.ca is a web portal listing service providers for people living with and at risk of HIV and hepatitis C in Canada, using Google Maps technology. For information on how to use HIV411/HCV411, see… Read more »
Posted On: Monday, August 17th, 2015
New and Noteworthy Two new Hep C medications added to Quebec provincial formulary Severe liver injury and liver failure common in a large sample of people with Hep C Adding ribavirin to Harvoni increased side effects but not cure rates
Posted On: Sunday, August 9th, 2015
World Hepatitis Day 2015: Strength through Community and Hope in Numbers Viral hepatitis can be prevented. It’s up to all of us to act. That is why in 2010 the World Health Organization made World Hepatitis Day one of only 4 official disease-specific world health days, to be observed each year on July 28th. Millions… Read more »
